PML

Showing 2 posts of 2 posts found.

Gilenya

EMA adds warning label to Novartis’ MS treatment Gilenya

December 22, 2015
Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya

Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …

Gilenya image

Gilenya to stay on US market – but with new safety warnings

May 15, 2012
Sales and Marketing EMA, FDA, Novartis, PML, gilenya

The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …

The Gateway to Local Adoption Series

Latest content